Ekso Bionics (NASDAQ:EKSO) Releases Earnings Results, Misses Expectations By $1.48 EPS

Ekso Bionics (NASDAQ:EKSO) issued its quarterly earnings results on Monday. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($1.48), FiscalAI reports. The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $5.03 million. Ekso Bionics had a negative return on equity of 90.71% and a negative net margin of 70.74%.

Ekso Bionics Stock Performance

EKSO stock traded down $0.54 during trading on Monday, hitting $10.64. 105,868 shares of the company traded hands, compared to its average volume of 285,826. Ekso Bionics has a 1 year low of $2.73 and a 1 year high of $13.27. The company has a market cap of $27.88 million, a PE ratio of -1.87 and a beta of 0.80. The stock’s 50-day simple moving average is $8.30 and its 200 day simple moving average is $5.78. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.66 and a quick ratio of 1.09.

Wall Street Analyst Weigh In

A number of research firms have issued reports on EKSO. HC Wainwright cut shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. Finally, Wall Street Zen raised Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $10.50.

Insider Buying and Selling

In other news, major shareholder Daniel Asher bought 15,540 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was purchased at an average cost of $12.30 per share, with a total value of $191,142.00. Following the acquisition, the insider directly owned 270,432 shares in the company, valued at $3,326,313.60. This trade represents a 6.10% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Ekso Bionics

A number of institutional investors have recently added to or reduced their stakes in EKSO. Citadel Advisors LLC acquired a new position in Ekso Bionics during the third quarter worth $198,000. Shay Capital LLC purchased a new stake in shares of Ekso Bionics during the third quarter worth about $67,000. Virtu Financial LLC acquired a new position in shares of Ekso Bionics during the 3rd quarter worth about $57,000. Finally, Geode Capital Management LLC lifted its stake in Ekso Bionics by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after buying an additional 10,281 shares in the last quarter. Institutional investors and hedge funds own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.